MREO Deadline: MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

Core Viewpoint - Mereo BioPharma Group plc is facing a securities fraud lawsuit, with a lead plaintiff deadline set for April 6, 2026, for investors who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Mereo provided misleading information regarding the expected results of its Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), claiming confidence in the drug's ability to reduce annualized fracture rates [5][6]. - Defendants are accused of making positive statements while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6]. Group 2: Class Action Participation - Investors who purchased Mereo ADSs during the specified class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To join the class action, investors can submit a form online or contact the Rosen Law Firm for more information [3][7].